Vor Bio taps ex-Sarepta exec as commercial head Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 8 August, 2025

Stay on the cutting edge of healthcare innovations with access to the latest insights. sponsored by HSBC

spotlight Novo keeps the lead in obesity pill battle against Lilly

news AbbVie and Genmab seek to expand use of T cell engager Epkinly Gilead says it 'hit the ground running' on its long-acting HIV shot launch Peer Review Vor Bio hires former Sarepta exec to lead commercial strategy; Mallinckrodt poaches CFO from Incyte

Principal - Life Science Alexandria Real Estate Equities San Francisco, CA, USA Senior Director of IT Caribou Biosciences, Inc. Berkeley, CA, USA Director Of Business Development, Health And Biomedical Innovation Brown University Providence, RI, USA Senior Patent Counsel Caribou Biosciences, Inc. Berkeley, CA, USA Head of Lab Operations Terray Therapeutics, Inc. Monrovia, CA, USA Principal Scientist, Molecular Design Terray Therapeutics, Inc. Monrovia, CA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Aug 21 2:00pm ET Agentic AI is here: Real-world applications in life sciences & healthcare sponsored by IBM

Big Pharma is doubling down. Startups are going all in. Who’s actually making AI work in drug R&D? Join the debate — online in the morning for everyone and in person for live-only content and a reception in the evening at NYC’s Georgia Room. Choose your pass today.

ENDPOINTS PHARMA Kennedy's mRNA cuts challenge Trump's Warp Speed achievements Updated: Two courts reject arguments against IRA in win for government Dewpoint downsizes while in 'final stages' of getting more funds for first trial New FDA program aims to speed up construction of US manufacturing sites  CDC adopts advisors' recommendation for Merck’s infant RSV antibody

in case you missed it 1. Lilly’s obesity pill is less effective than Novo’s, pivotal data suggest 2. Updated: Lilly CEO pushes back on Trump’s drug price plan, as obesity data overshadow revenue beat •  Merck KGaA joins other drugmakers in considering direct-to-patient US sales  3.